树突状细胞融合瘤苗在肿瘤免疫中的研究进展  被引量:1

Study progress about dendritic/tumor fusion cell-based vaccine in tumor immunotherapy

在线阅读下载全文

作  者:谢军平(综述)[1] 侯晓华[1] 陶晓南(审校)[1] 

机构地区:[1]华中科技大学同济医学院附属协和医院,武汉430022

出  处:《国际肿瘤学杂志》2008年第9期664-667,共4页Journal of International Oncology

摘  要:树突状细胞(DC)是诱导初始免疫应答反应的专职抗原提呈细胞,它能捕获抗原并加工处理成小分子多肽,通过MHCⅠ类和Ⅱ类分子提呈给T细胞和B细胞。DC与肿瘤细胞融合所获得的融合瘤细胞,在共刺激信号存在的条件下,能够加工处理细胞内许多已知和未知的肿瘤相关抗原(TAA),并通过MHCⅠ类和Ⅱ类分子提呈。目前,DC融合瘤苗在动物和临床研究中取得了许多进展,已成为肿瘤免疫治疗的热点之一。Dendritic cells (DCs) are potent professional antigen-presenting cells which are able to in- duce primary immune responses. DC can capture and process antigens into small-molecule peptides and present them to T cells and B cells through MHC class Ⅰ and Ⅱ molecules. An alternative approach to the induction of antitumor immunity is the use of fusion of DC and tumor cells. In this approach, a broad spectrum of known and unknown tumor-associated antigens (TAA) are presented by MHC class Ⅰ and Ⅱ molecules. In animal and clinical studies, dendritic/tumor fusion ceil-based vaccine has made much progress and become a focus of the tumor immunotherapy.

关 键 词:树突细胞 癌症疫苗 抗原 肿瘤相关 T淋巴细胞 细胞毒性 

分 类 号:R730.51[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象